Events

Rappel de i-STAT1 Analyser when used with i-STAT Celite Activated Clotting Time (ACT) & Kaolin ACT Cartridges. An in vitro diagnostic medical device (IVD).i-STAT1 Analyser – software version JAMS142E i-STAT Celite ACT Cartridges

Selon Department of Health, Therapeutic Goods Administration, ce/cet/cette rappel concerne un dispositif en/au/aux/à Australia qui a été fabriqué par Abbott Australasia Pty Ltd Point-of-Care Division.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    RC-2017-RN-00225-1
  • Classe de risque de l'événement
    Class III
  • Date de mise en oeuvre de l'événement
    2017-02-15
  • Pays de l'événement
    Australia
  • Source de l'événement
    DHTGA
  • URL de la source de l'événement
    https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2017-RN-00225-1
  • Notes / Alertes
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notes supplémentaires dans les données
  • Cause
    Abbott point of care inc. has determined that celite act and kaolin act cartridges may produce falsely low results when very high clotting time samples are tested when using i-stat1 analyser software version jams142e. patient samples with a measured clot time of >853 seconds for celite and >1134 seconds for kaolin may display results of approximately 100 to 200 seconds. the typical therapeutic range of the i-stat act assay is 200 to 600 seconds and results in this range are not affected by this issue. only individual patient results where the measured clot time is >853 seconds for celite act and >1134 seconds for kaolin act are impacted. the i-stat system provides the user with an ongoing estimate of the clot time as the act cartridges are running, referred to as the count up bar. the count up bar is not impacted by this issue. the ongoing estimates that the user receives during the cartridge run are correct.
  • Action
    To correct the issue, Abbott is advising customers to update all i-STAT analysers performing Celite ACT or Kaolin ACT testing with software version JAMS142G, which is available from the Abbott Point of Care website. A look back of results is not required, as results obtained within the typical therapeutic range of 200 to 600 seconds are not affected, only individual patient results where the measured clot time is >853 seconds for Celite ACT and >1134 seconds for Kaolin ACT are impacted and monitoring of the activated clotting time is happening in real time during a procedure. This action has been closed-out on 04/07/2017.

Device

i-STAT1 Analyser when used with i-STAT Celite Activated Clotting Time (ACT) & Kaolin ACT Cartridg...
  • Modèle / numéro de série
    i-STAT1 Analyser when used with i-STAT Celite Activated Clotting Time (ACT) & Kaolin ACT Cartridges. An in vitro diagnostic medical device (IVD).i-STAT1 Analyser – software version JAMS142E i-STAT Celite ACT CartridgesList Number: 03P86-25i-STAT Kaolin ACT CartridgesList Number: 03P87-25ARTG Numbers: 203350, 213851
  • Manufacturer
    Abbott Australasia Pty Ltd Point-of-Care Division

Manufacturer

Abbott Australasia Pty Ltd Point-of-Care Division
  • Société-mère du fabricant (2017)
    Abbott Laboratories
  • Commentaire du fabricant
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DHTGA